Chemoinformaics analysis of ENT-KAURAN-16BETA,17-DIOL
| Molecular Weight | 306.49 | nRot | 1 |
| Heavy Atom Molecular Weight | 272.218 | nRig | 19 |
| Exact Molecular Weight | 306.256 | nRing | 4 |
| Solubility: LogS | -4.814 | nHRing | 0 |
| Solubility: LogP | 4.614 | No. of Aliphatic Rings | 4 |
| Acid Count | 0 | No. of Aromatic Rings | 0 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 4 |
| Atoms Count | 56 | No. of Aliphatic Hetero Cycles | 0 |
| No. of Heavy Atom | 22 | No. of Aromatic Carbocycles | 0 |
| nHetero | 2 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 2 | No. Saturated Carbocycles | 4 |
| No. of Hydrogen atom | 34 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 20 | No. of Saturated Rings | 4 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 0 |
| No. of Oxygen atom | 2 | No. of Arom Bond | 0 |
| nHA | 2 | APOL | 57.675 |
| nHD | 2 | BPOL | 34.109 |
| QED | 0.764 |
| Synth | 5.532 |
| Natural Product Likeliness | 3.499 |
| NR-PPAR-gamma | 0.018 |
| Lipinski | Accepted |
| Pfizer | Rejected |
| GSK | Rejected |
| Golden Triangle | Accepted |
| Pgp-inh | 0.021 |
| Pgp-sub | 0 |
| HIA | 0.006 |
| CACO-2 | -4.896 |
| MDCK | 0.0000156 |
| BBB | 0.734 |
| PPB | 0.949136 |
| VDSS | 1.37 |
| FU | 0.0500525 |
| CYP1A2-inh | 0.026 |
| CYP1A2-sub | 0.373 |
| CYP2c19-inh | 0.05 |
| CYP2c19-sub | 0.86 |
| CYP2c9-inh | 0.191 |
| CYP2c9-sub | 0.492 |
| CYP2d6-inh | 0.048 |
| CYP2d6-sub | 0.692 |
| CYP3a4-inh | 0.493 |
| CYP3a4-sub | 0.156 |
| CL | 13.567 |
| T12 | 0.099 |
| hERG | 0.015 |
| Ames | 0.013 |
| ROA | 0.036 |
| SkinSen | 0.089 |
| Carcinogencity | 0.027 |
| EI | 0.234 |
| Respiratory | 0.895 |
| NR-Aromatase | 0.824 |
| Antiviral | No |
| Prediction | 0.667593 |